727 related articles for article (PubMed ID: 6151890)
1. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
Lund-Johansen P
Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combined alpha-beta-blockade. I.
Louis WJ; McNeil JJ; Drummer OH
Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889
[TBL] [Abstract][Full Text] [Related]
3. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
Koch G
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular dynamics after acute and long-term alpha- and beta-adrenoceptor blockade at rest, supine and standing, and during exercise.
Koch G
Br J Clin Pharmacol; 1979; 8(Suppl 2):101S-105S. PubMed ID: 43162
[TBL] [Abstract][Full Text] [Related]
5. Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.
Lund-Johansen P; Omvik P
Cardiovasc Drugs Ther; 1991 Jun; 5(3):605-15. PubMed ID: 1678963
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade.
Koch G
J Cardiovasc Pharmacol; 1981; 3 Suppl 1():S30-41. PubMed ID: 6169958
[TBL] [Abstract][Full Text] [Related]
7. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Prichard BN
Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
[TBL] [Abstract][Full Text] [Related]
8. Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension.
Svendsen TL; Rasmussen S; Hartling OJ; Nielsen PE; Trap-Jensen J
Postgrad Med J; 1980; 56 Suppl 2():21-6. PubMed ID: 7433338
[TBL] [Abstract][Full Text] [Related]
9. Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
Roberts DH; Tsao Y; Grimmer SF; Winstanley PA; Orme ML; Breckenridge AM
Br J Clin Pharmacol; 1987 Aug; 24(2):163-72. PubMed ID: 2887190
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.
Lund-Johansen P
J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S12-7. PubMed ID: 2464093
[TBL] [Abstract][Full Text] [Related]
11. Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.
Joekes AM; Thompson FD
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):789-93. PubMed ID: 990156
[TBL] [Abstract][Full Text] [Related]
12. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
[TBL] [Abstract][Full Text] [Related]
13. Effect of an alpha- and beta-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension.
Bahlmann J; Brod J; Hubrich W; Cachovan M; Pretschner P
Br J Clin Pharmacol; 1979; 8(Suppl 2):113S-117S. PubMed ID: 526390
[TBL] [Abstract][Full Text] [Related]
14. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses.
Prida XE; Hill JA; Feldman RL
Am J Cardiol; 1987 May; 59(12):1084-8. PubMed ID: 2883869
[TBL] [Abstract][Full Text] [Related]
15. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
Brittain RT; Levy GP
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
[TBL] [Abstract][Full Text] [Related]
16. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
Lammintausta R; Koulu M; Allonen H
Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
[TBL] [Abstract][Full Text] [Related]
17. Labetalol: a review of its pharmacology and therapeutic use in hypertension.
Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1978 Apr; 15(4):251-70. PubMed ID: 25757
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.
Lund-Johansen P
Am J Med; 1983 Oct; 75(4A):24-31. PubMed ID: 6638038
[TBL] [Abstract][Full Text] [Related]
19. The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
Lund-Johansen P
Clin Nephrol; 1992; 38 Suppl 1():S78-86. PubMed ID: 1363538
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic effects of intravenous labetalol in essential hypertension.
Dunn FG; Oigman W; Messerli FH; Dreslinski GR; Reisin E; Frohlich ED
Clin Pharmacol Ther; 1983 Feb; 33(2):139-43. PubMed ID: 6822026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
